ASP-8062, or ASP8062, is a GABA<sub>B</sub> receptor positive allosteric modulator which is under development for the treatment of alcoholism. It was also under development for the treatment of fibromyalgia and opioid-related disorders, but development for these indications was discontinued. The drug is taken orally.
It shows analgesic and antiaddictive effects in animals. In a polysomnography study, ASP-8062 dose-dependently enhanced slow wave sleep (SWS; deep sleep) without affecting REM sleep in humans. It also dose-dependently increased growth hormone (GH) release. The time to peak levels of ASP-8062 in humans is 1 to 4hours and its elimination half-life is approximately 40 to 50hours.
ASP-8062 is under development by Astellas Pharma in collaboration with the National Institute on Alcohol Abuse and Alcoholism (NIAAA). As of June 2023, it is in phase 2 clinical trials for alcoholism. The drug is the most advanced GABA<sub>B</sub> receptor positive allosteric modulator in clinical trials as of 2024.